Sort   by:  
 Page size 
TranscriptomicsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers [methylation]
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidin...
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57342 | biostudies-arrayexpress
TranscriptomicsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57343 | biostudies-arrayexpress
UnknownRandomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
Not available
S-EPMC6756041 | biostudies-literature
GenomicsRomidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL
We demonstrate that the combination of the HDAC inhibitor, romidepsin, and the demethylating agent, azacitidine, exerts synergistic anti-proliferative effects and induction of apoptosis involving activation of the caspase cascade in CTCL cell lines as well as CD4+ T cells derived from patients with ...
ORGANISM(S): Homo sapiens 
2016-03-30 | E-GEOD-66732 | biostudies-arrayexpress
TranscriptomicsEffect of AZA on gene expression of multiple breast, colon, and ovarian cell lines [expression]
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidin...
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57341 | biostudies-arrayexpress
TranscriptomicsIdentification of genes that may predict response to azacitidine treatment.
Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Approximately 50% of patients do not respond to AZA and have very poor outcomes. It is of great interest to identify predictive biomarkers for AZA responsiveness. Therefore, we s...
ORGANISM(S): Homo sapiens 
2016-02-10 | E-GEOD-77750 | biostudies-arrayexpress
ClinicalAzacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
This phase II trial is studying how well giving azacitidine together with entinostat works in treating patients with metastatic colorectal cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping the...
2087731 | ecrin-mdr-crc
ClinicalStudy of Azacitidine and Durvalumab in Advanced Solid Tumors
This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab patients with microsatellite stable colorectal carcinoma (MSS-CRC), pla...
2218156 | ecrin-mdr-crc
GenomicPhase I/II Study of Revlimid/Azacitidine

This single-arm study design has been selected to investigate the safety of combination therapy with Vidaza® (azacitidine) and Revlimid® (lenalidomide) in a population of 18 participants with advanced MDS for the Phase I portion, and 18 participants for the Phase II portion. The multi-c...

phs001318 | dbGaP
TranscriptomicsmiRNA profiling of the MV4-11 cell line treated with trabectidin or azacitidin
In order to study the effects of trabectedin in chronic myelomonocytic leukemia and in juvenile myelomonocytic leukemia, we performed whole genome transcriptional profiling of a model cell line treated under either the reference drug for CMML / JMML (Azacitidine) or trabectedin.
ORGANISM(S): Homo sapiens 
2017-04-30 | E-MTAB-2979 | biostudies-arrayexpress
Sort   by:  
 Page size